The new indication adds to Imfinzi's FDA-approved indications in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), which have helped drive sales of the PD-L1 inhibitor to $1.3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback